S. Gertler - Concepedia

Author

S. Gertler

University of Ottawa

Also Known As

S Z Gertler, S. Gertler, S. Z. Gertler, S.Z Gertler, S.Z. Gertler, Stan Gertler, Stan Z. Gertler

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of Ottawa Ottawa Hospital Ottawa Regional Cancer Foundation Ottawa Hospital Research Institute Baylor College of Medicine

About

S. Gertler is an author at University of Ottawa specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	527
2	Health Sciences	3	3	58
3	Social Sciences	2	2	95
4	Nursing	1	1	43
5	Allergy	1	1	13

S. Gertler

Publications

Citations

H-Index

Page 1

	Year	Citations
Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial C. Kent Osborne, John Pippen, Stephen E. Jones, Journal of Clinical Oncology	2002	643
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women J.F.R. Robertson, C. Kent Osborne, Anthony Howell, Cancer	2003	312
A Selective N-Type Ca<sup>2+</sup>-Channel Blocker Prevents CA1 Injury 24 h following Severe Forebrain Ischemia and Reduces Infarction following Focal Ischemia Alastair M. Buchan, S. Gertler, Hui Li, Journal of Cerebral Blood Flow & Metabolism	1994	142
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine Kurt A. Jaeckle, Surasak Phuphanich, Martin J. van den Bent, British Journal of Cancer	2001	119
Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer J.F.R. Robertson, Björn Erikstein, Kent C. Osborne, Clinical Pharmacokinetics Breast OncologyOncologyIntramuscular FulvestrantMedicineBreast Cancer	2004	101
Preference weights for chemotherapy side effects from the perspective of women with breast cancer Iryna Kuchuk, Nathaniel Bouganim, K. Beusterien, Breast Cancer Research and Treatment Breast OncologyOncologyPreference WeightsCancer ManagementChemotherapy Side Effects	2013	94
Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects Kathleen Beusterien, Jessica Grinspan, Iryna Kuchuk, The Oncologist	2014	83
Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials L. Mauriac, John Pippen, J. Albano, European Journal of Cancer Second-line TreatmentNon-visceral MetastasesAdvanced Breast CancerSurgical OncologyBreast Oncology	2003	69
The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study Dominique Frechette, Lise Paquet, Shailendra Verma, Breast Cancer Research and Treatment Sexual HealthEndocrine-related CancerSexual DysfunctionGynecologyWomen's Health	2013	52
Risk Model–Guided Antiemetic Prophylaxis vs Physician’s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer Mark Clemons, Nathaniel Bouganim, Stephanie Smith, JAMA Oncology	2015	48

Page 1